A previous study indicates that VGLL4 binds to IRF2BP2 to promote PD‐L1 expression and induces immune evasion through IRF2 inhibition in lung cancer.23 The binding of VGLL4 to IRF2BP2 also activates the expression of VEGF‐A in muscle cells.24 This evidence implies that IRF2BP2 may cross talk with Hippo pathway and CTGF via binding to VGLL4. Here, IRF2BP2 is linked to lung carcinoma.